Lilly’s Foundayo Launches Nationwide at $25–$149 Monthly While Trogenix Glioblastoma Data Shows 83% Tumor Eradication
Eli Lilly’s Foundayo, a once-daily oral GLP-1 weight-loss pill taken without food or water restrictions, launched nationwide at $149/month self-pay and $25/month with commercial coverage. Trogenix published preclinical glioblastoma data showing 83% tumor eradication in mice with no toxicity and plans Phase I/II patient dosing in Q2 2026.
1. Foundayo Now Available Nationwide
Eli Lilly’s Foundayo (orforglipron) is now shipping to U.S. retail pharmacies and accessible through LillyDirect and telehealth providers. The once-daily oral GLP-1 receptor agonist can be taken any time of day without food or water restrictions and starts at $149 per month for self-pay patients or as low as $25 per month with commercial insurance coverage. In the ATTAIN-1 trial, participants on the highest dose lost an average of 27.3 pounds versus 2.2 pounds with placebo, while all treated individuals lost 25 pounds compared to 5.3 pounds in the placebo group.
2. Trogenix Reports Preclinical Glioblastoma Success
Trogenix’s Synthetic Super-Enhancer gene therapy achieved complete tumor eradication in 83% of mice in an aggressive glioblastoma model with no observed toxicity. The dual-payload approach combines direct tumor killing with immune activation and is set to begin patient dosing in a Phase I/II clinical trial in Q2 2026.